Dissecting the Nature and Determinants of Sympathetic Nerve Activity in Patients With COPD

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The project will be pursued in our respiratory, autonomic nervous system physiology laboratory (Respiratory, autonomic nervous system physiology laboratory, Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital; Head of Department: Professor Michael Dreher). Overactivity of the sympathetic nerve activity (SNA) axis with centrally increased heart rate and peripheral vasoconstriction is a known phenomenon in patients with systolic heart failure (HF) and has recently been described in patients with primary lung disease as seen in chronic obstructive pulmonary disease (COPD). However, systematic analyses on this clinically relevant topic are currently lacking. Thus, using a comprehensive, multimodal approach and state-of-the-art technology, this research project is designed to determine the extent and nature of increased SNA in COPD (AIM 1) and evaluate the underlying mechanisms (AIM 2). The project will address the following hypotheses: 1. In COPD, concomitant obstructive sleep apnea is independently associated with increased SNA. 2. Precapillary pulmonary hypertension (PH), inspiratory muscle dysfunction and systemic inflammation describe a COPD phenotype characterised by increased SNA with a different subtype.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Age ≥ 18

• Ability and willingness to give informed consent to participate in the study

Locations
Other Locations
Germany
RWTH Aachen University
RECRUITING
Aachen
Contact Information
Primary
Michael Dreher, Professor
mdreher@ukaachen.de
+492418088763
Backup
Jens Dr. Spiesshoefer, MD
jspiesshoefe@ukaachen.de
+492418037036
Time Frame
Start Date: 2022-05-10
Estimated Completion Date: 2024-08
Participants
Target number of participants: 80
Treatments
COPD patients (n=60)
The following parameters will be determined in 60 consecutive patients with COPD without established cardiovascular disease (i.e. without an indication for beta blocker therapy or other pharmacological treatments attacking on the neurohormonal pathways like angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists).~1. OSA severity.~2. Determination of PH and right HF severity (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography;~3. Comprehensive lung function and inspiratory muscle function testing ;Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis;~4. Assessment of systemic inflammation
Controls (n=20)
(and in a group of healthy controls \[3:1\] matched for age, sex and BMI).
Sponsors
Leads: RWTH Aachen University

This content was sourced from clinicaltrials.gov